Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice
- PMID: 10103180
- PMCID: PMC89206
- DOI: 10.1128/AAC.43.4.777
Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice
Abstract
The Helicobacter pylori SS1 mouse model was used to characterize the development of resistance in H. pylori after treatment with metronidazole monotherapy and to examine the effect of prior exposure to metronidazole on the efficacy of a metronidazole-containing eradication regimen. Mice colonized with the metronidazole-sensitive H. pylori SS1 strain were treated for 7 days with either peptone trypsin broth or the mouse equivalent of 400 mg of metronidazole once a day or three times per day (TID). In a separate experiment, H. pylori-infected mice were administered either peptone trypsin broth or the mouse equivalent of 400 mg of metronidazole TID for 7 days, followed 1 month later by either peptone trypsin broth or the mouse equivalent of 20 mg of omeprazole, 250 mg of clarithromycin, and 400 mg of metronidazole twice a day for 7 days. At least 1 month after the completion of treatment, the mice were sacrificed and their stomachs were cultured for H. pylori. The susceptibilities of isolates to metronidazole were assessed by agar dilution determination of the MICs. Mixed populations of metronidazole-resistant and -sensitive strains were isolated from 70% of mice treated with 400 mg of metronidazole TID. The ratio of resistant to sensitive strains was 1:100, and the MICs for the resistant strains varied from 8 to 64 micrograms/ml. In the second experiment, H. pylori was eradicated from 70% of mice treated with eradication therapy alone, compared to 25% of mice pretreated with metronidazole (P < 0.01). Mice still infected after treatment with metronidazole and eradication therapy contained mixed populations of metronidazole-resistant and -sensitive isolates in a ratio of 1:25. These results demonstrate that H. pylori readily acquires resistance to metronidazole in vivo and that prior exposure of the organism to metronidazole is associated with failure of eradication therapy. H. pylori-infected mice provide a suitable model for the study of resistance mechanisms in H. pylori and will be useful in determining optimal regimens for the eradication of resistant strains.
Similar articles
-
Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.Antimicrob Agents Chemother. 2000 Oct;44(10):2623-9. doi: 10.1128/AAC.44.10.2623-2629.2000. Antimicrob Agents Chemother. 2000. PMID: 10991835 Free PMC article.
-
The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.Helicobacter. 2000 Dec;5(4):196-201. doi: 10.1046/j.1523-5378.2000.00030.x. Helicobacter. 2000. PMID: 11179983 Clinical Trial.
-
Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.Helicobacter. 2013 Dec;18(6):459-67. doi: 10.1111/hel.12062. Epub 2013 May 29. Helicobacter. 2013. PMID: 23714140 Clinical Trial.
-
Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.J Antimicrob Chemother. 2003 Feb;51(2):367-71. doi: 10.1093/jac/dkg057. J Antimicrob Chemother. 2003. PMID: 12562704
-
Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit.Aust N Z J Med. 1999 Aug;29(4):512-6. doi: 10.1111/j.1445-5994.1999.tb00752.x. Aust N Z J Med. 1999. PMID: 10868529
Cited by
-
Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.Antimicrob Agents Chemother. 2003 Jul;47(7):2249-55. doi: 10.1128/AAC.47.7.2249-2255.2003. Antimicrob Agents Chemother. 2003. PMID: 12821476 Free PMC article.
-
Mouse-colonizing Helicobacter pylori SS1 is unusually susceptible to metronidazole due to two complementary reductase activities.Antimicrob Agents Chemother. 2000 Nov;44(11):3127-32. doi: 10.1128/AAC.44.11.3127-3132.2000. Antimicrob Agents Chemother. 2000. PMID: 11036035 Free PMC article.
-
Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.J Clin Microbiol. 2003 Nov;41(11):5011-4. doi: 10.1128/JCM.41.11.5011-5014.2003. J Clin Microbiol. 2003. PMID: 14605132 Free PMC article.
-
Helicobacter pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa.Infect Immun. 2003 Apr;71(4):2022-31. doi: 10.1128/IAI.71.4.2022-2031.2003. Infect Immun. 2003. PMID: 12654822 Free PMC article.
-
Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.Antimicrob Agents Chemother. 2000 Oct;44(10):2623-9. doi: 10.1128/AAC.44.10.2623-2629.2000. Antimicrob Agents Chemother. 2000. PMID: 10991835 Free PMC article.
References
-
- Adamek R J, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxycillin—influence on treatment outcome. Am J Gastroenterol. 1998;93:386–389. - PubMed
-
- Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, Alampi G, Nicolini G, Sottili S, Simoni P, Roda A, Roda E. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 1998;12:439–445. - PubMed
-
- Becx M C, Janssen A J H M, Clasener H A L, de Koning R W. Metronidazole-resistant Helicobacter pylori. Lancet. 1990;335:539–540. - PubMed
-
- Bell G D, Powell K, Burridge S M, Pallecaros A, Jones P H, Gant P W, Harrison G, Trowell J E. Experience with “triple” anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992;6:427–435. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical